Biomarkers for personalised prevention of chronic diseases: a common protocol for three rapid scoping reviews
- PMID: 38824585
- PMCID: PMC11143646
- DOI: 10.1186/s13643-024-02554-9
Biomarkers for personalised prevention of chronic diseases: a common protocol for three rapid scoping reviews
Abstract
Introduction: Personalised prevention aims to delay or avoid disease occurrence, progression, and recurrence of disease through the adoption of targeted interventions that consider the individual biological, including genetic data, environmental and behavioural characteristics, as well as the socio-cultural context. This protocol summarises the main features of a rapid scoping review to show the research landscape on biomarkers or a combination of biomarkers that may help to better identify subgroups of individuals with different risks of developing specific diseases in which specific preventive strategies could have an impact on clinical outcomes. This review is part of the "Personalised Prevention Roadmap for the future HEalThcare" (PROPHET) project, which seeks to highlight the gaps in current personalised preventive approaches, in order to develop a Strategic Research and Innovation Agenda for the European Union.
Objective: To systematically map and review the evidence of biomarkers that are available or under development in cancer, cardiovascular and neurodegenerative diseases that are or can be used for personalised prevention in the general population, in clinical or public health settings.
Methods: Three rapid scoping reviews are being conducted in parallel (February-June 2023), based on a common framework with some adjustments to suit each specific condition (cancer, cardiovascular or neurodegenerative diseases). Medline and Embase will be searched to identify publications between 2020 and 2023. To shorten the time frames, 10% of the papers will undergo screening by two reviewers and only English-language papers will be considered. The following information will be extracted by two reviewers from all the publications selected for inclusion: source type, citation details, country, inclusion/exclusion criteria (population, concept, context, type of evidence source), study methods, and key findings relevant to the review question/s. The selection criteria and the extraction sheet will be pre-tested. Relevant biomarkers for risk prediction and stratification will be recorded. Results will be presented graphically using an evidence map.
Inclusion criteria: Population: general adult populations or adults from specific pre-defined high-risk subgroups; concept: all studies focusing on molecular, cellular, physiological, or imaging biomarkers used for individualised primary or secondary prevention of the diseases of interest; context: clinical or public health settings.
Systematic review registration: https://doi.org/10.17605/OSF.IO/7JRWD (OSF registration DOI).
Keywords: Biomarkers; Cancer; Cardiovascular diseases; Chronic diseases; Neoplasm; Neurodegenerative diseases; Personalised prevention; Precision Medicine; Precision prevention.
© 2024. The Author(s).
Conflict of interest statement
There are no conflicts of interest in this project.
Similar articles
-
The current landscape of personalised preventive approaches for non-communicable diseases: A scoping review.PLoS One. 2025 Jan 13;20(1):e0317379. doi: 10.1371/journal.pone.0317379. eCollection 2025. PLoS One. 2025. PMID: 39804869 Free PMC article.
-
The Effectiveness of Integrated Care Pathways for Adults and Children in Health Care Settings: A Systematic Review.JBI Libr Syst Rev. 2009;7(3):80-129. doi: 10.11124/01938924-200907030-00001. JBI Libr Syst Rev. 2009. PMID: 27820426
-
Beyond the black stump: rapid reviews of health research issues affecting regional, rural and remote Australia.Med J Aust. 2020 Dec;213 Suppl 11:S3-S32.e1. doi: 10.5694/mja2.50881. Med J Aust. 2020. PMID: 33314144
-
The future of Cochrane Neonatal.Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12. Early Hum Dev. 2020. PMID: 33036834
-
Engagement of patients and the public in personalised prevention in Europe using genomic information: a scoping review.Front Public Health. 2024 Sep 12;12:1456853. doi: 10.3389/fpubh.2024.1456853. eCollection 2024. Front Public Health. 2024. PMID: 39346592 Free PMC article.
Cited by
-
Integrating omics data and machine learning techniques for precision detection of oral squamous cell carcinoma: evaluating single biomarkers.Front Immunol. 2024 Dec 3;15:1493377. doi: 10.3389/fimmu.2024.1493377. eCollection 2024. Front Immunol. 2024. PMID: 39691710 Free PMC article.
-
Behavioral and biomedical factors associated with lifestyle modification practices among diagnosed hypertensive patients in pastoral health facilities of southern Ethiopia.Front Cardiovasc Med. 2024 Dec 24;11:1450263. doi: 10.3389/fcvm.2024.1450263. eCollection 2024. Front Cardiovasc Med. 2024. PMID: 39776863 Free PMC article.
-
Multiple Exposures of Plasma to Nanoparticles: A Novel Tool to Personalize Biomolecular Coronas and Fractionate Fluids.Anal Chem. 2025 Jul 15;97(27):14132-14141. doi: 10.1021/acs.analchem.4c05573. Epub 2025 Jun 30. Anal Chem. 2025. PMID: 40587098 Free PMC article.
References
-
- Council of European Union. Council conclusions on personalised medicine for patients (2015/C 421/03). Brussels: European Union; 2015 dic. Report No.: (2015/C 421/03). Disponible en: https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:52015XG121....
-
- FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource. Silver Spring (MD): Food and Drug Administration (US); 2016 [citado 3 de febrero de 2023]. Disponible en: http://www.ncbi.nlm.nih.gov/books/NBK326791/. - PubMed
-
- Porta M, Greenland S, Hernán M, dos Silva I S, Last JM. International Epidemiological Association, editores. A dictionary of epidemiology. 6. Oxford: Oxford Univ. Press; 2014. p. 343.
-
- PROPHET . Project kick-off meeting. Rome. 2022.